JP6866379B2 - 神経発達障害療法 - Google Patents

神経発達障害療法 Download PDF

Info

Publication number
JP6866379B2
JP6866379B2 JP2018536130A JP2018536130A JP6866379B2 JP 6866379 B2 JP6866379 B2 JP 6866379B2 JP 2018536130 A JP2018536130 A JP 2018536130A JP 2018536130 A JP2018536130 A JP 2018536130A JP 6866379 B2 JP6866379 B2 JP 6866379B2
Authority
JP
Japan
Prior art keywords
mice
day
syndrome
rett syndrome
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502716A (ja
JP2019502716A5 (https=
Inventor
クリストファー ユー． ミスリング，
クリストファー ユー． ミスリング，
Original Assignee
アナベックス ライフ サイエンシズ コーポレイション
アナベックス ライフ サイエンシズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57966177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6866379(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アナベックス ライフ サイエンシズ コーポレイション, アナベックス ライフ サイエンシズ コーポレイション filed Critical アナベックス ライフ サイエンシズ コーポレイション
Publication of JP2019502716A publication Critical patent/JP2019502716A/ja
Publication of JP2019502716A5 publication Critical patent/JP2019502716A5/ja
Application granted granted Critical
Publication of JP6866379B2 publication Critical patent/JP6866379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018536130A 2016-01-26 2017-01-24 神経発達障害療法 Active JP6866379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287062P 2016-01-26 2016-01-26
US62/287,062 2016-01-26
PCT/US2017/014702 WO2017132127A1 (en) 2016-01-26 2017-01-24 Neurodevelopmental disorder therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021010835A Division JP7153950B2 (ja) 2016-01-26 2021-01-27 神経発達障害療法

Publications (3)

Publication Number Publication Date
JP2019502716A JP2019502716A (ja) 2019-01-31
JP2019502716A5 JP2019502716A5 (https=) 2020-03-05
JP6866379B2 true JP6866379B2 (ja) 2021-04-28

Family

ID=57966177

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018536130A Active JP6866379B2 (ja) 2016-01-26 2017-01-24 神経発達障害療法
JP2021010835A Active JP7153950B2 (ja) 2016-01-26 2021-01-27 神経発達障害療法
JP2022153402A Pending JP2022173373A (ja) 2016-01-26 2022-09-27 神経発達障害療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021010835A Active JP7153950B2 (ja) 2016-01-26 2021-01-27 神経発達障害療法
JP2022153402A Pending JP2022173373A (ja) 2016-01-26 2022-09-27 神経発達障害療法

Country Status (5)

Country Link
US (5) US10507196B2 (https=)
EP (2) EP3407880B1 (https=)
JP (3) JP6866379B2 (https=)
CA (1) CA3012199C (https=)
WO (1) WO2017132127A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132127A1 (en) * 2016-01-26 2017-08-03 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
US11337953B2 (en) 2016-07-27 2022-05-24 Anavex Life Sciences Corp. A2-73 as a therapeutic for insomnia, anxiety, and agitation
JP7532718B2 (ja) * 2018-04-12 2024-08-14 アナベックス ライフ サイエンス コーポレイション 物質のａ２－７３結晶多形組成物およびそれらの使用方法
AU2019269739B2 (en) 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
EP3990114A4 (en) * 2019-06-26 2023-08-02 The Regents of the University of California Methods and compositions for treating smith-magenis syndrome
US20220249427A1 (en) * 2019-07-22 2022-08-11 Anavex Life Sciences Corp. Anavex2-73 for the treatment of genetic neurodevelopmental disorders
US12397197B2 (en) 2023-11-08 2025-08-26 CaddyHack, Inc. Dynamic data collection and systematic processing system
WO2025231180A1 (en) * 2024-05-01 2025-11-06 Anavex Life Sciences Corp. Blarcamesine correction of eeg biomarkers in fragile x syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
GR1004208B (en) 2001-10-15 2003-04-04 Αλεξανδρος Βαμβακιδης Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel ligands, with synergic sigma/muscarinic (neuroactivating) and sigma/sodium channel (neuroprotective) components, as prototypical activating - neuroprotectors and neuroregenerative drugs
FR2897535B1 (fr) 2006-02-21 2012-07-20 Alexandre Vamvakides Les sigma ligands : (mono- ou di-alkylaminoalkyl)-y- butyrolactones, leurs analogues aminotetrodrafuranes et les (1-adamantyl) benzene(s) alkylamines en tant que modulateurs prototypiques des recepteurs cellulaires
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
GR1005865B (el) * 2007-01-17 2008-04-07 Anavex Life Sciences Corp. Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.
CA2689549A1 (en) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders
GR1006794B (el) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
WO2011109398A2 (en) * 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2012055826A1 (en) 2010-10-25 2012-05-03 Universite De La Mediterranee (Aix-Marseille Ii) TREATMENT OF MeCP2-ASSOCIATED DISORDERS
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
US10555916B2 (en) * 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
WO2017132127A1 (en) * 2016-01-26 2017-08-03 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
AU2019269739B2 (en) * 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment

Also Published As

Publication number Publication date
US20200246303A1 (en) 2020-08-06
EP3407880A1 (en) 2018-12-05
US10888543B2 (en) 2021-01-12
EP3407880B1 (en) 2022-08-17
JP2019502716A (ja) 2019-01-31
JP7153950B2 (ja) 2022-10-17
US11839600B2 (en) 2023-12-12
EP4104831A1 (en) 2022-12-21
US20240066003A1 (en) 2024-02-29
JP2022173373A (ja) 2022-11-18
CA3012199C (en) 2024-05-07
US20190022052A1 (en) 2019-01-24
US11446275B2 (en) 2022-09-20
JP2021063136A (ja) 2021-04-22
US20220387373A1 (en) 2022-12-08
US10507196B2 (en) 2019-12-17
CA3012199A1 (en) 2017-08-03
US20210228532A1 (en) 2021-07-29
WO2017132127A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
JP6866379B2 (ja) 神経発達障害療法
EP3442513B1 (en) Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders
Stein et al. Opioids: from physical pain to the pain of social isolation
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
WO2011020061A2 (en) Compositions and methods of for treating bipolar disorder
WO2011107583A1 (en) Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2011042812A1 (en) Use of rasagiline for the treatment of progressive supranuclear palsy
US20200188358A1 (en) Methods for the treatment of depression
McDOUGLE et al. Risperidone in adults with autism or pervasive developmental disorder
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
Yamada et al. Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats
Pometlová et al. Cross-fostering effect on postnatal development of rat pups exposed to methamphetamine during gestation and preweaning periods
WO2019161179A1 (en) Methods of treating developmental syndromes with pde10a inhibitors
HK40083948A (en) A2-73 for treating angelman syndrome, williams syndrome smith-magenis syndrome and multiple sclerosis
Riddle et al. Plasma MHPG: within-and across-day stability in children and adults with Tourette's syndrome
US20170007596A1 (en) Treatment of multiple sclerosis with combination of laquinimod and flupirtine
HK40000642B (en) Treatment of rett syndrome with the compound a2-73
HK40000642A (en) Treatment of rett syndrome with the compound a2-73
WO2026052068A1 (zh) 药物组合物的用途
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder
Hening et al. P0022 Types and time-course of adverse events in 3 double-blind trials of pramipexole for restless legs syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210407

R150 Certificate of patent or registration of utility model

Ref document number: 6866379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250